Micro-injection-mediated hematopoietic stem cell gene therapy
Over the past decade, significant attention has been devoted to the development of viral vectors (i.e., retrovirus, lentivirus, adeno-associated virus) and conditions capable of transducing hematopoietic stem cells. After several years of disappointing results, recent reports in humans and other primates, most particularly the French report of successful treatment of X-linked severe combined immune deficiency (SCID) [1.], indicate that viral approaches will be successful in treating specific hematopoietic diseases. However, it is clear that alternate non-viral methods of gene delivery and genetic modification offer significant advantages, and may in fact be the only effective approach for treating certain blood diseases. In this review, we focus on glass needle-mediated micro-injection as a method for the delivery of genetic material into blood stem cells, with an emphasis on molecules capable of either compensating gene deletions/mutations or directly repairing gene mutations.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2000 |
---|---|
Erschienen: |
2000 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
---|---|
Enthalten in: |
Current opinion in molecular therapeutics - 2(2000), 4 vom: 15. Aug., Seite 412-9 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Davis, B R [VerfasserIn] |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 12.04.2001 Date Revised 20.11.2014 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM111605237 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM111605237 | ||
003 | DE-627 | ||
005 | 20231222155949.0 | ||
007 | tu | ||
008 | 231222s2000 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0372.xml |
035 | |a (DE-627)NLM111605237 | ||
035 | |a (NLM)11249771 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Davis, B R |e verfasserin |4 aut | |
245 | 1 | 0 | |a Micro-injection-mediated hematopoietic stem cell gene therapy |
264 | 1 | |c 2000 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 12.04.2001 | ||
500 | |a Date Revised 20.11.2014 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Over the past decade, significant attention has been devoted to the development of viral vectors (i.e., retrovirus, lentivirus, adeno-associated virus) and conditions capable of transducing hematopoietic stem cells. After several years of disappointing results, recent reports in humans and other primates, most particularly the French report of successful treatment of X-linked severe combined immune deficiency (SCID) [1.], indicate that viral approaches will be successful in treating specific hematopoietic diseases. However, it is clear that alternate non-viral methods of gene delivery and genetic modification offer significant advantages, and may in fact be the only effective approach for treating certain blood diseases. In this review, we focus on glass needle-mediated micro-injection as a method for the delivery of genetic material into blood stem cells, with an emphasis on molecules capable of either compensating gene deletions/mutations or directly repairing gene mutations | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a RNA |2 NLM | |
650 | 7 | |a 63231-63-0 |2 NLM | |
650 | 7 | |a DNA |2 NLM | |
650 | 7 | |a 9007-49-2 |2 NLM | |
700 | 1 | |a Brown, D B |e verfasserin |4 aut | |
700 | 1 | |a Prokopishyn, N L |e verfasserin |4 aut | |
700 | 1 | |a Yannariello-Brown, J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current opinion in molecular therapeutics |d 1999 |g 2(2000), 4 vom: 15. Aug., Seite 412-9 |w (DE-627)NLM111603668 |x 2040-3445 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2000 |g number:4 |g day:15 |g month:08 |g pages:412-9 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 2 |j 2000 |e 4 |b 15 |c 08 |h 412-9 |